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Abstract
Recent advances in cancer biology have revealed that many malignancies possess a hierarchal system, and leukemic stem
cells (LSC) or leukemia-initiating cells (LIC) appear to be obligatory for disease progression. Acute promyelocytic leukemia
(APL), a subtype of acute myeloid leukemia characterized by the formation of a PML-RARa fusion protein, leads to the
accumulation of abnormal promyelocytes. In order to understand the precise mechanisms involved in human APL
leukemogenesis, we established a humanized in vivo APL model involving retroviral transduction of PML-RARA into CD34
+
hematopoietic cells from human cord blood and transplantation of these cells into immunodeficient mice. The leukemia
well recapitulated human APL, consisting of leukemic cells with abundant azurophilic abnormal granules in the cytoplasm,
which expressed CD13, CD33 and CD117, but not HLA-DR and CD34, were clustered in the same category as human APL
samples in the gene expression analysis, and demonstrated sensitivity to ATRA. As seen in human APL, the induced APL cells
showed a low transplantation efficiency in the secondary recipients, which was also exhibited in the transplantations that
were carried out using the sorted CD34
2 fraction. In order to analyze the mechanisms underlying APL initiation and
development, fractionated human cord blood was transduced with PML-RARA. Common myeloid progenitors (CMP) from
CD34
+/CD38
+ cells developed APL. These findings demonstrate that CMP are a target fraction for PML-RARA in APL, whereas
the resultant CD34
2 APL cells may share the ability to maintain the tumor.
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Introduction
Acute myeloid leukemia (AML) constitutes a heterogeneous
group of tumors in myeloid lineage cells characterized by the
proliferation and accumulation of immature myeloblasts [1].
Recent advances in cancer biology have revealed that various
genetic events result in the blockage of differentiation with
subsequent uncontrolled cellular proliferation. In addition, in vivo
analyses using a xenograft model with immunodeficient mice have
shown that a very immature subset of AML cells called leukemic
stem cells (LSC), which are typically characterized as CD34
+/
CD38
2 cells, as observed in normal hematopoietic stem cells
(HSCs), have been shown to slowly undergo cell division to both
yield progenitor cells and sustain the LSC population, thus
resulting in the maintenance of the tumor [2–6]. More recently,
several reports have shown that CD34
+/CD38
+ hematopoietic
progenitors are able to acquire the ability to maintain populations
of LSC or leukemia-initiating cells (LIC) [7]. It is therefore possible
that the phenotypes of LIC differ among the subtypes of AML.
Acute promyelocytic leukemia (APL) is a subset of AML defined
by the formation of a chimeric gene, promyelocytic leukemia-
retinoic acid receptor a (PML-RARA) [8]. It is characterized by
the accumulation of abnormal promyelocytes with abundant large
azurophilic granules, suggesting that APL cells undergo matura-
tion arrest in the later steps of myeloid differentiation. The typical
pattern of cellular surface markers of APL is positive for CD13,
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presumed to indicate cellular immaturity, and HLA-DR [9]. It is
very difficult to engraft primary APL samples in immunodeficient
mice. They did not become engrafted into the NOD/SCID mice
to any degree [3]. In NOD/Shi-SCID/IL-2Rc
null (NOG) mice,
which are more profoundly immunocompromised than NOD/
SCID mice [10,11], six out of eight APL samples were not
engrafted or only very little engrafted [12]. It is therefore possible
that the mechanisms underlying the development of APL differ
from those involved in the pathogenesis of AML uncovered to
date. Elucidating the pathogenesis of APL is important for
improving the treatment of APL patients, and will provide clues
to understand the development of other subtypes of AML.
In vivo analyses using transgenic APL mice models with PML-
RARA have revealed that a population of committed myeloid
progenitor cells (CD34
+, c-kit
+,F c cRIII/II
+, Gr1
int) was identified
as the APL-LIC [13,14]. However, the cellular surface antigens
and the gene expression pattern in humans are different from
those in mice. In particularly, in transgenic systems, murine APL
developed after a long latent period through a myelodysplastic/
proliferative phase, which does not usually precede human APL
[15–18]. There have been no in vivo models for exploring
leukemogenesis of human APL to date; largely because human
primary APL cells are difficult to engraft as a xenograft [3,12].
PML-RARA-retrovirally transduced human CD34
+ cells from
cord blood have therefore only been evaluated in vitro [19].
Therefore, the aim of this study was to establish a humanized
xenograft APL model using the retroviral transduction of PML-
RARA into human CD34
+ cells and NOG mice in order to
investigate the mechanisms of APL leukemogenesis, such as that
involving disease initiation and maintenance in the model.
Materials and Methods
Fractionation of human hematopoietic cells from cord
blood
Cord blood (CB) and patients’ APL samples were obtained after
written informed consent was provided in accordance with the
Declaration of Helsinki and with approval from the Tokai
University Committee on Clinical Investigation (Permit number:
#12I-46 and #12I-49). CD34 positive and negative specimens
were primarily prepared using the CD34 Progenitor Cell Isolation
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD34
+ cells
were then purified again using anti-human CD34 mAbs (Beckman
Coulter, Brea, CA), in combination with or without an anti-CD38
antibody (BD, Franklin Lakes, NJ), with a FACS vantage
instrument (BD). CD34
2/CD33
+ cells were also purified again
using anti-human CD34 and CD33 mAbs (Beckman Coulter) and
the FACS vantage instrument. The preparation of common
myeloid progenitors (CMP), granulocyte-monocytic progenitors
(GMP) and megakaryocyte-erythrocyte progenitors (MEP) was
performed using an anti-CD123 antibody (BD) and anti-CD45RA
(Biolegend, San Diego, CA) antibody, according to a previous
report [20].
Retrovirus transduction of PML-RARA into human
hematopoietic cells
The MIGR1 retroviral vector [21] or MIGR1-PML-RARA
(bcr3/short form) [22] in combination with the vesicular stomatitis
virus-G protein (VSV-G) envelope vector (pCMV-VSV-G) was
transiently transfected into PLAT-gp cells using the Fugene 6
transfection reagent (Roche Diagnostics, Basel, Switzerland). The
culture supernatant was concentrated 100 to 200 times by
ultracentrifugation. After overnight culture of the fractionated
cells in StemPro-34 (Life Technologies, Carlsbad, CA) with TPO,
SCF, and FLT3 ligand (50 ng/ml each), they were incubated with
the concentrated supernatant on retronectin-coated plates (Ta-
kara-Bio, Otsu, Japan). Retroviral transduction was performed
twice, and then transplantation was performed the next day.
Colony-forming unit-cells assay
PML-RARA transduced cells were sorted by their EGFP, CD34
and CD38 expression by FACS vantage 48 h after infection. The
colony-forming unit-cells (CFU-C) assay was performed as
described previously [23]. The fluorescent images were captured
using a HS All-in-One Fluorescence Microscope Biorevo 9000
(Keyence Corporation, Osaka, Japan) and were analyzed by the
BZ II software program (Keyence Corporation).
RNA extraction and RT-PCR
Total RNA was isolated using the RNeasy micro kit (Qiagen,
Hilden, Germany) or Isogen (Nippon gene, Tokyo, Japan), and the
reverse-transcribed cDNA was amplified by qualitative PCR. The
qualitative-PCR analysis was performed by SRL Inc. (Hachioji,
Tokyo, Japan). The sequences of PCR primers and probes were
shown in Table S1.
Transplantation, serial transplantation and ATRA
treatment
Nine- to 20-week-old NOD/Shi-scid, IL-2Rcc
null (NOG) mice
[10,11] were irradiated with 220 cGy of X-rays. On the following
day, the whole infected cells or primary AML cells were
intravenously injected. The EGFP-positive cells in the peripheral
blood were monitored. The mice with induced APL were defined
as those bearing more than 0.1% EGFP
+ cells which dominantly
expressed CD33 (more than 70%) in their bone marrow at four
months after transplantation. In the initial analysis, the occurrence
of APL was confirmed by the morphological observations using
cytospin slides after EGFP sorting. For serial transplantation, bone
marrow cells were obtained from recipient mice, and the sorted
EGFP-positive cells were injected intravenously or intramedullary
into the irradiated mice [24]. The engrafted mice were treated
intraperitoneally with 1.5 mg/g of body weight/day of all-trans
retinoic acid (ATRA, Sigma) for 21 days [25], and were then
sacrificed to collect the EGFP-positive cells in the bone marrow by
sorting. All the experiments using animals were approved by the
animal care committee of Tokai University (Permit number:
#132028).
Flow cytometric analysis
The cells were stained with APC-conjugated anti-human CD45,
CD33, CD34, HLA-DR (Beckman Coulter), CD13, and CD117
(BD) mAbs. They were subjected to flow cytometry using a
FACSCalibur instrument (BD) and the CellQuest software
program (BD).
Cell preparation, Wright-Giemsa staining and
immunofluorescence microscopy
Cytospin slides were prepared using a Cytospin 4 Cytocen-
trifuge (Thermo Scientific, Waltham, MA) at 500 rounds per
minute for 5 min. To observe the cellular morphology, Wright-
Giemsa staining was performed. For the immunofluorescent study,
cells were seeded onto poly-L-lysine coated slides and fixed with
ice cold 70% ethanol for 15 min. After permeabilization with
0.2% Triton X-100 for 20 min, the slides were treated with PBS
containing 5% normal goat serum for 1 hour to block the
nonspecific binding of antibodies. The anti-PML antibody (Merck
APL Mice Model Using PML-RARA-Transduced Human CMP
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counterstained with DAPI. Images were captured with an
LSM510 META confocal microscope (Carl Zeiss, Oberkochen,
Germany) and processed using Adobe Photoshop 7.0 (Adobe
Systems, San Jose, CA).
Southern blot analysis
Genomic DNA was extracted from the cells using a DNeasy kit
(Qiagen). Ten micrograms of the DNA were electrophoresed and
transferred to nylon membranes (Hybond-N+, GE Healthcare,
Fairfield, CT). The DNA was then crosslinked to the membrane
by ultraviolet light. The EGFP probe was prepared from MIGR1
vector by cutting it using NcoI and SalI, and was labeled with
32P-
dCTP using the Rediprime II DNA Labelling System (GE
Healthcare). The membrane was hybridized with the probe in
Rapid-hyb buffer (GE Healthcare), and was analyzed by a
Phosphoimager (LAS1000, Fuji Film, Tokyo, Japan).
Microarray
Total RNA was labeled and hybridized to Affymetrix Human
Genome U133 Plus 2.0 Array GeneChip microarrays (Affymetrix,
Santa Clara, CA) using the manufacturer’s protocols. The results
were deposited in the Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/; accession no. GSE49344). The
microarray data from normal human promyelocytes and clinical
samples bearing AML, including APL, were obtained from the
deposited data on the GEO (GSE12662). The APL-specific
expressed genes have been described in detail in a previous study
[26]. The probe set data were generated using standard
normalization algorithms included in the Affymetrix Microarray
Suite software program, v.5 (MAS5.0). The clustering analysis was
performed by the Gene spring GX software program, version 11
(Agilent technology, Santa Clara, CA).
To identify the genes that are differentially expressed in a
specific cellular subset, all probe sets with fewer than 10% present
calls in both groups and a coefficient of variation ,0.5 across all
samples were eliminated prior to the subsequent analysis; (i) The
genes differently expressed in the induced APL cases among the
AML cases were defined as genes whose expression change
(upregulation or downregulation) was $2.0 fold in comparison to
those in AML other than APL, (ii) The genes associated with
immaturity in the induced APL cases were expressed at
significantly higher levels in CD34
+ cells than the other normal
cells (FDR ,0.05, fold-change .2.0 upregulated), and were also
expressed in the induced APL cells at similar levels (induced APL:
CD34
+ $1:1), and moreover, these genes were expressed at higher
levels in promyelocytes (induced APL: Pros $2:1). (iii) The genes
upregulated during promyelocyte differentiation were expressed at
significantly higher levels in promyelocytes than in the other
normal cells (FDR ,0.05, fold-change .2.0 upregulated), and
were expressed at lower levels in the induced APL (induced APL:
Pros #1:2), (iv) The genes induced by PML-RARA were
expressed at higher levels in the induced APL than in all the
normal cells (induced APL: normal $2:1), and were not expressed
in any normal cells (more than 75% absent calls, as summarized
by the MAS5.0). Statistical significance was assessed by the
unpaired unequal variance Welch test (P,0.05), and correction
for multiple testing was performed by the Benjamini and
Hochberg False Discovery Rate (FDR), using a cutoff of 0.05.
The gene set specific for induced APL was defined to fulfill one
or more of the above criteria (ii) to (iv) in the gene set identified in
(i).
The integration site analysis of PML-RARA using linear
amplification-mediated PCR
To identify the genomic-proviral junction sequence, linear
amplification-mediated polymerase chain reaction (LAM-PCR)
was performed as described previously, with minor modifications
[27,28]. In brief, genomic DNA from bone marrow cells was first
digested with Tsp509I. A linear amplification of target DNA in the
digested genome was performed by repeated primer extension
using a vector-specific 59-biotinylated primer, LTR1.5, and Taq
polymerase. After selection with Dynabeads MyOne Streptavidin
C1 (Life Technologies), a double-stranded asymmetrical linker
cassette was ligated to the Tsp509I-digested site using T4 DNA
Ligase. The DNA products were then amplified by PCR using a
vector-specific primer, LTR3, and linker cassette primer, LC1.
The nested PCR was performed using internal primers LTR5 and
LC2. The final products were sequenced after cloning them into
the TOPO TA cloning vector (Life Technologies). The primer
sequences are shown in Table S1.
Statistical analyses
The Kaplan-Meier method was used to estimate the leukemia-
free survival (LFS) of mice. Log-rank p values were used for
comparisons of the LFS among three subgroups. The analyses
were conducted using the GraphPad Prism software package
(GraphPad Software, La Jolla, CA). The other statistical analyses
were performed using the Mann-Whitney U Test with the IBM
SPSS Statistics software program (New York, NY). Values of p,
0.05 were considered to be statistically significant.
Results
Functions of PML-RARa in human CD34 cells in vitro
To examine the functions of PML-RARa in vitro, a MIGR1-
PML-RARA or MIGR1 control vector was retrovirally infected
into human CD34
+ cells from cord blood. The transduction
efficiency evaluated by EGFP positivity was 0.5% to 18.6%
(n=10, median: 5.7%) and 2.1% to 19.7% (n=25, median:
6.8%), respectively. The expression of PML-RARA in these cells
was confirmed by RT-PCR (Figure S1). The induction of PML-
RARA in CD34
+ cells disrupted PML nuclear bodies by
interacting with wild-type PML via the PML portion of the
chimeric transcript, and the distribution of PML in the nucleus
was altered to show a microspeckled pattern in these cells [29–31]
(Figure 1A). Additionally, the induction of PML-RARA reduced
all the colony formation capacity (Figure 1B). The PML-RARA
expression was confirmed in these colonies by EGFP fluorescence
(Figure S1 and S2) and RT-PCR, although the expression levels
were 37 times lower compared to those in the CD34
+ cells
48 hours after PML-RARA transduction (Figure S3). Regarding
the content of colonies, MIGR1-infected CD34
+ cells mainly
generated the erythroid lineage-containing colonies, such as CFU-
mix and BFU-E, whereas more than half of the colonies from the
CD34
+ cells with PML-RARA were of the myeloid lineage, like
CFU-GM (Figures 1C). These data demonstrate that PML-
RARA induces the myeloid commitment of human CD34
+ cells.
Establishment of a humanized in vivo APL model
The cells transduced with PML-RARA or the MIGR1 control
vector were then transplanted into NOG mice. The EGFP
+ cells
survived and proliferated three to four months after transplanta-
tion only in the NOG mice transplanted with PML-RARA-, not
control vector at all, infected human CD34
+ cells. The median
proportion of EGFP
+/CD45
+ cells in the bone marrow obtained
from the transplanted mice was 23.7% (0.95% to 96.5%, n=24)
APL Mice Model Using PML-RARA-Transduced Human CMP
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+/human
CD45
+ cells expressed human CD33 (70.2% to 100%, median
90.6%, n=24) (Figure 2B), thus suggesting that they were of the
myeloid lineage. The PML-RARA expression was detected only in
the EGFP
+ fraction and not in the EGFP
2 fraction of the sorted
human CD45
+/CD33
+ cells from the NOG mice (Figure 2C).
The expression levels of PML-RARA were decreased about 17-
fold in comparison to those in the CD34
+ cells 48 hours after
PML-RARA transduction (Figure S3), but the presence of PML-
RARA in the human myeloid cells, recognized as EGFP
+ cells,
caused marked accumulation of promyelocytes, in comparison to
the control EGFP
2 human myeloid cells (52.8% in EGFP
+ cells vs
19.4% EGFP
2 cells in the 13 paired samples, p,0.0001). On the
other hand, the proportions of myeloblasts, mature neutrophils
and monocytes were decreased (5.2% vs 14.4%, p=0.010; 2.5%
vs 12.7%, p=0.005; 4.0% vs 10.1%, p=0.016) (Figure 2D).
These findings confirmed that the expression of PML-RARA
induced the myeloid differentiation of human CD34
+ cells and
blocked them at the promyelocytic stage. Morphologically, the
promyelocytes had abundant large azurophilic granules and round
nuclei with a high nucleocytoplasmic ratio. Some of them had a
number of Auer bodies and looked like Faggot cells, which are the
typical morphological features of APL cells, and were not seen in
the previous murine models (Figure 2E). A Southern blot analysis
using an EGFP probe revealed that the EGFP
+/CD45
+/CD33
+
cells oligoclonally proliferated in vivo (Figure 2F).
The induced APL cells were detected in 24 out of the 34 mice
(71%) transplanted with PML-RARA-transduced CD34 cells
(p=0.0184 in comparison to the control). They were detected in
all 16 mice when the calculated number of the transplanted
EGFP
+/CD34
+ cells per mouse was more than 3,000 (4,655 to
29,728 cells, median: 11,085 cells) (p=0.0006 in comparison to
the control). On the other hand, they were only detected in eight
out of 18 mice (44%) transplanted with EGFP
+/CD34
+ cells at a
Figure 1. The function of PML-RARA in human CD34
+ cells in vitro. (A) The results of an immunofluorescent analysis of PML distribution in
human CD34
+ cells transduced with PML-RARA. The images were captured with an LSM510 META confocal microscope (Carl Zeiss). The bars indicate
10 mm. (B) The colony-forming assay using PML-RARA-transduced CD34
+ cells. The cells were sorted by EGFP expression 48 h after infection. Colony
formation was evaluated on days 10 to 12 after plating the cells. The average numbers of colonies from three independent experiments are shown.
Data represent the means 6 SD. The asterisks (*) indicate p,0.05. (C) The proportion of each kind of colony was calculated from the results of the
colony-forming assay shown in (B). The percentages of CFU-GM are higher in PML-RARA-infected cells than in control (MIGR1) cells (p=0.013).
doi:10.1371/journal.pone.0111082.g001
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(p=0.093 in comparison to the control) (Figure 2G). This
proportion was not dependent on the number of transplanted
EGFP
+/CD34
+ cells.
These findings demonstrate that a humanized APL model can
be successfully established by the transplantation of PML-RARA–
transduced human CD34 cells into NOG mice.
Characteristics of the induced APL cells obtained from
the humanized in vivo model
The induced APL cells were positive for human myeloid
markers such as CD13, CD33 and CD117, and were negative for
CD34 and HLA-DR, as seen in typical human APL [32]. PML-
RARA did not contribute to the development of lymphocytes.
Human CD19
+ B-cells in the spleen and human CD4
+/CD8
+ T-
cells in the thymus were negative for EGFP (Figure 3A).
To evaluate the gene expression of the induced APL cells, a
microarray analysis was performed, and the expression of the 510
APL-specific genes identified in a previous study was compared
with that observed in the clinical AML samples [26]. Two clinical
APL samples from our patients were simultaneously evaluated and
were aligned in the APL category defined in the study, suggesting
that our microarray results were comparable with those in the
previous study. The induced APL cells from our models were also
classified into the APL category when compared to normal
promyelocytes and AML samples other than APL (Figure 3B).
In common with this previous study [26], the 3,439 probes
(3278 genes) differentially expressed in the induced APL and the
AML other than APL ((i) in the Materials and Methods) grouped
the induced APL and human primary APL together, separately
from the other types of AML (Figure S4). The gene sets whose
expression in the induced APL cases was not dependent on the
myeloid differentiation were also filtered by comparison with the
data for normal myeloid cells. They included the genes for
immaturity expressed in the induced APL (1,782 probes, including
1,720 genes), the genes upregulated in promyelocyte differentia-
tion not in the induced APL (447 probes, including 427 genes) and
the genes specifically induced by PML-RARA (466 probes,
including 429 genes) ((ii), (iii) and (iv) in the Materials and
Methods). Each gene set was analyzed using the DAVID website
Figure 2. Establishment of humanized APL in vivo. (A) The proportion of EGFP
+/human CD45
+ cells in the bone marrow of leukemic NOG mice.
Each dot represents a single mouse. The horizontal line represents the median value. (B) The proportion of CD33
+ cells among the EGFP
+/human
CD45
+ cells in the bone marrow of the leukemic NOG mice. Each dot represents a single mouse. The horizontal line represents the median value. (C)
The expression of PML-RARA in RT-PCR was detected only in the EGFP
+ fraction obtained from the engrafted human CD45
+/CD33
+ cells. The cells
were obtained from bone marrow 16 weeks after transplantation. B2M, beta 2 microglobulin. The PML-RARA expression vector and human CD34
+ cells
were used as a positive control for the PML-RARA and B2M analysis, respectively. (D) The differential counts of the engrafted CD45
+/CD33
+/EGFP
+ and
EGFP
2 cells from the mice transplanted with PML-RARA-induced human CD34
+ cells. They were obtained from bone marrow 16 to 20 weeks after
transplantation. The data represent the means. (E) A representative photograph of the resulting leukemic cells which morphologically recapitulated
APL. Faggot cells were recognized, as seen in the right top corner. The images were captured with a BX41 microscope (Olympus). The bar indicates
10 mm. (F) The results of a Southern blot analysis of the genomic DNA from induced APL cells with an EGFP probe. Clonal bands are shown by arrow
heads: white, seen in both BM and SP; orange, seen only in BM or SP. BM, bone marrow; SP, spleen. (G) The leukemia-free duration in NOG mice
transplanted with PML-RARA-transduced CD34
+ cells.
doi:10.1371/journal.pone.0111082.g002
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related to N-Glycan, steroid and heparan sulfate biosynthesis, the
spliceosome and pyrimidine metabolism were expressed similar to
the levels in normal CD34
+ cells, and those related to the MAPK
signaling pathway were exclusively expressed in comparison to
normal myeloid cells, including normal CD34
+ cells. On the other
hand, the genes related to neurotrophin signaling and the cell
cycle, as well as those associated with metabolic processes, such as
glycolysis/gluconeogenesis, the pentose phosphate pathway and
sphingolipid metabolism were downregulated (Table S2), thus
suggesting that the induced APL exhibited dysregulated signaling
and metabolism as differentiated myeloid cells. Additionally, the
gene set composed of 573 probes including 547 genes, which
fulfilled one or more above criteria (ii) to (iv) in the gene set
identified in (i), clearly separated the normal and malignant
promyelocytes, such as those of induced and human primary APL
(Figure S5 and Table S3), as described in the previous study
using primary APL cases [26].
To evaluate the additional genetic events that accompanied the
integration of PML-RARA in the genome, the insertion sites of
PML-RARA were analyzed. Some of the integration sites of
PML-RARA were in the introns or exons of genes (Table S4).
However, they were neither recurrent nor found in the previous
whole genome sequence analysis of the APL patients [33]. These
findings suggest that PML-RARA was a common key event, but
that there were various additional genetic events in these induced
APL cells, and this finding was compatible with the previous
analysis using human primary APL [33].
The induced APL cells differentiated into mature neutrophils
following treatment with all-trans retinoic acid (ATRA) in vitro
(Figures 4A and 4B), which was accompanied by alterations in
the PML distribution in the nucleus, from a microspeckled to a
speckled pattern (Figure 4C). Similarly, ATRA induced transient
myeloid differentiation in vivo (n=4), as has been seen in APL
patients (Figures 4D and 4E).
These findings demonstrate that our induced APL cells
recapitulate human APL both phenotypically and functionally.
Re-transplantable cellular fraction in the induced APL
cells
It is necessary to prove that the resultant induced APL cells
possess the reproducibility of APL in the secondary recipients in
order to demonstrate their capacity for leukemogenesis. However,
previous studies have revealed that primary APL cells exhibit
difficultly in engrafting in immunodeficient mice [3,12]. When the
induced APL cells were transplanted into the second recipients,
they were proven to be re-transplantable intravenously; 500,000 to
1,000,000 leukemic cells, but not 50,000 cells, were required, and
the frequency of APL cells in the secondary recipients was low
(0.04% to 1.41%, n=6). The frequency was still low, even though
Figure 3. Characteristics of the induced APL in vivo. (A) The representative expression pattern of cell surface markers in the induced APL cells
determined by a flow cytometric analysis. All the scatter plots show the relationships between the EGFP positivity and cell surface marker expression.
The whole living cells gated as a propidium iodide-negative fraction in the bone marrow were analyzed. The induced APL cells were recognized as
EGFP
+ cells. A few murine hematopoietic cells, recognized as a human CD45
2 fraction, were detected in this mouse. (B) The heat map of the
microarray analysis using the 510 APL-specific genes for the comparison of the induced APL cells (purple, n=3) with APL (red, n=16), other types of
AML (M0, 1, 2 and 4 in FAB classification, green, n=62) and normal promyelocytes (blue, n=5) in a previous study [26]. The red triangles (n=2) for a
total 16 APL cases show the clinical APL samples whose microarray data were obtained in this study.
doi:10.1371/journal.pone.0111082.g003
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n=2) (Figure 5A). The immunophenotype of the engrafted cells
was the same as that seen in the primary induced APL cells: they
were positive for CD13 and CD33, without the expression of
CD34 or HLA-DR (Figure 5B), demonstrating that the induced
APL retains self-renewal capacity with a low level of transplan-
Figure 4. The induction of myeloid differentiation in the APL cells induced by ATRA treatment in vitro and in vivo. (A) Cytospin slides
of the induced APL cells cultured with or without 1 mM ATRA for 6 days. The mature neutrophils with Auer rods are seen in the ATRA-treated group.
The images were captured with a BX41 microscope (Olympus). The bar indicates 10 mm. (B) The differential cellular counts of the induced APL cells
cultured with or without ATRA. The average leukocyte differentiation in three independent experiments is shown. (C) The results of an
immunofluorescent analysis of the PML distribution in the induced APL cells before and after treatment with ATRA. The images were captured with
an LSM510 META confocal microscope (Carl Zeiss). All the bars indicate 10 mm. (D, E) The induction of myeloid differentiation in the induced APL cells
by ATRA in vivo. The secondary recipients transplanted with the induced APL cells were then intraperitoneally treated with ATRA for 21 days. Cytospin
slides of EGFP
+/hCD45
+/hCD33
+ cells from the secondary recipients transplanted with the induced APL cells are shown (D). The images were
captured with a BX41 microscope (Olympus). The bar indicates 10 mm. Their differentiated cellular counts were evaluated, and the representative
series data are indicated (E).
doi:10.1371/journal.pone.0111082.g004
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for engraftment in this xenograft model differed between the
CD34
+ cells transduced with PML-RARA and the APL cells
mostly composed of the CD34
2 fraction.
To identify a fraction responsible for the APL maintenance in
the induced APL cases, CD34
+ and CD34
2 APL fractions were
separately collected and transplanted intravenously. The CD34
+
fraction was pooled because there were very few CD34
+ cells in
each induced APL case (Figures 3A and 5B). The CD34
2
fraction was sorted twice to exclude the CD34
+ fraction
completely. Fifty thousand APL cells in both the CD34
+ and
CD34
2 fractions failed to engraft in the secondary recipients (0 out
of 4 mice in each fraction). Similar to the unsorted cells, one
million CD34
2 fraction cells were able to engraft in recipient mice
(4 out of 4 mice) (Figures 5C and 5D).
These findings revealed that CD34
2 induced APL cells exhibit
the ability to function as APL-LIC in vivo, although the LIC
function was not excluded in the CD34
+ APL fraction.
The CD34
+/CD38
+ progenitors trigger APL by PML-RARA
induction in vivo
The findings that the PML-RARA transduced-CD34
+ cells
developed APL while the resultant CD34
2 APL cells exhibited
transplantability indicate the possibility that the initiation and
maintenance of APL arise at different steps of differentiation,
which are not likely to involve the CD34
+/CD38
2 fraction, as
Figure 5. APL-LIC in the humanized APL in vivo model. (A) The engraftment of the induced APL cells in the secondary recipients. The bone
marrow cells were obtained 16 weeks after transplantation and evaluated. Each dot represents a single mouse. (B) The immunophenotype of the
induced APL cells in the secondary recipients. The representative pattern is shown. (C) The engraftment capacity in each fraction from the induced
APL cells in the secondary recipients. The bone marrow cells were obtained 16 weeks after transplantation and evaluated. (D) The engraftment of the
CD34
2 fraction in the secondary recipients. The engrafted cells are shown as EGFP
+/CD45
+ cells.
doi:10.1371/journal.pone.0111082.g005
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a cellular target for PML-RARA that effectively develops APL,
PML-RARA was transduced into fractionated cells: CD34
+/
CD38
2, CD34
+/CD38
+ and CD34
2/CD33
+ cells from the cord
blood (Figures 6A and 6B). The transduction efficiency, as
evaluated by EGFP expression, ranged from 1.9% to 5.0%
(median: 3.53%, n=6) in CD34
+/CD38
2 cells, 4.5% to 10.6%
(median: 10.07%, n=6) in CD34
+/CD38
+ cells and 19.1% to
22.1% (median: 20.63%, n=4) in CD34
2/CD33
+ cells. Because
the CD34
+ fraction from human cord blood possessed a higher
proportion of CD34
+/CD38
+ (74.5% to 94.2%) than that of
CD34
+/CD38
2 cells, the presumed absolute number of PML-
RARA transplanted cells was higher in CD34
+/CD38
+ cells than
in CD34
+/CD38
2 cells (3,430 to 31,800 cells vs 140 to 450 cells
per mouse; 22,900 to 27,700 CD34
2/CD33
+ cells). One hundred
unfractionated human CD34
+ cells, including both CD34
+/
CD38
2 and CD34
+/CD38
+ cells, were engrafted with multi-
lineage differentiation in our previous study [10], thus suggesting
that the transplanted cell numbers were adequate for engraftment
in the NOG mice. The induction of PML-RARA in CD34
+/
CD38
+ cells reduced the colony formation capacity and favored
the formation of myeloid colonies, as seen in CD34
+ cells
(Figures 1B and 1C). On the other hand, the induction of
PML-RARA in CD34
+/CD38
2 cells generated very few colonies
in comparison to the MIGR1 control vector-infected CD34
+/
CD38
2 cells (Figures 6C and 6D). Consistent with the results,
the induced APL cells were detected mostly in the mice
transplanted with CD34
+/CD38
+ cells (median, 16.4% in the
whole bone marrow cells) (Figure 6E). These findings suggest
that CD34
+/CD38
+ progenitors proliferate and survive more
efficiently than CD34
+/CD38
2 cells in vitro and trigger APL in
vivo by inducing PML-RARA.
Human common myeloid progenitors develop into APL
by inducing PML-RARA among CD34
+/CD38
+ progenitors
In order to identify the detailed target fraction in CD34
+/
CD38
+ cells that generates APL with PML-RARA, the CD34
+/
CD38
+ cells were then divided into three fractions based on their
expression of CD123 and CD45RA; CMP, GMP and MEP
(Figure 6F). The retroviral transduction efficiencies of PML-
RARA into CMP, GMP and MEP were 6.0% to 15.2% (median:
6.6%, n=9), 3.3% to 8.8% (median: 7.1%, n=8), and 7.8% to
24.6% (median: 8.5%, n=7) (Figure 6G), and the presumed
absolute numbers of PML-RARA transduced cells in CMP, GMP
and MEP utilized for the transplantation were 5,850 to 15,200,
830 to 4,250, and 1,150 to 2,550 cells per mouse, respectively,
which were deduced to directly reflect their proportion in the
human cord blood. The frequency of induced APL cells in whole
bone marrow cells from transplanted NOG mice was higher when
using CMP (median, 25.2%) than GMP and MEP (median, 0.15%
and 0.01%, respectively) (Figure 6H).
Taken together, these findings obtained using our humanized in
vivo APL model demonstrate that CMP are a target fraction for
PML-RARA in the development of APL.
Discussion
Our present study revealed that a humanized APL model was
successfully established by transplantation of human CD34
+ cord
blood transduced with PML-RARA into immunodeficient mice.
Using this model, we demonstrated that the CMP develop into
APL by transducing PML-RARA whereas the resultant CD34
2
APL cells had the ability to maintain the tumor. Our system
improves in the following points: The induced APL cells were
detected in all of the mice within 150 days if more than 3,000
human CD34
+ cells infected with PML-RARA were transplanted
into NOG mice. The resultant leukemia well recapitulated the
human disease phenotypically, genetically and functionally,
including the presence of Auer rods and Faggot cells, and the
expression pattern of cellular surface markers and transcripts, as
well as ATRA sensitivity and low leukemia transplantability.
These findings demonstrated that this humanized in vivo model is
suitable for prospectively analyzing the process of APL develop-
ment in humans.
The cellular subset from which the APL originates is still
controversial. Several lines of evidence using in vivo experiments
have suggested that APL arises in the committed myeloid
progenitors, whereas several clinical observations using FISH
and RT-PCR analyses suggest that APL arises in earlier
progenitors [4]. A recent report using conditional knock-in mice
showed that the induction of PML-RARA led to dominant
proliferation in a stem cell compartment with multilineage
potential, but did not result in myeloproliferation, as if the stem
cell compartment would not support leukemogenesis in this model
[34,35]. Our in vitro and in vivo findings are compatible with the
previous findings which showed that the generation of PML-
RARA transgenic mice was only possible by expressing PML-
RARA in early myeloid cells using the human cathepsin G (hCG)
and MRP8 promoters, not the promoters of b-actin, a house-
keeping gene, and CD11b which is expressed at a later stage of
myeloid differentiation [36].
The leukemogenic function of PML-RARa may require subtle
myeloid differentiation, as seen in CMP in the present study;
PML-RARa has been reported to possess the inhibitory or toxic
effects on the cellular survival, senescence or apoptosis [18,37,38].
CMP are still immature enough to easily acquire stemness and are
already committed to the myeloid lineage, which may allow PML-
RARA to dysregulate RARa-dependent myelopoiesis, rather than
hematopoietic stem cells, in agreement with the fact that RARA is
implicated in the regulation of myelopoiesis, including both early
stage and terminal differentiation. In this scenario, the expression
of PML-RARA would induce differentiation of CMP to promy-
elocytes, but inhibit their terminal differentiation at the same time
[19,39,40]. Therefore, if the CMP expressing PML-RARA
acquires stemness, this can result in the development of APL.
Our findings showed no engraftment of CD34
+/CD38
2 cells with
PML-RARA transduction in vivo, although their leukemogenic
activity cannot be denied, as fewer cells were transplanted in
comparison to the CD34
+/CD38
+ cells. Further analyses are
required to evaluate whether CD34
+/CD38
2 cells possess the
ability to cause APL.
Xenograft models using immunodeficient mice are at present
the only method for evaluating the maintenance of human
leukemia as LIC. The induced APL generated in the NOG mice
had a low engraftment efficiency; however, this biological feature
well-reproduced the properties of APL cells found in human
patients [3,12]. It is possible that the difficulty associated with
engrafting APL cells, both primary samples and induced APL cells
obtained from cord blood, into NOG mice may depend on the
different preferences of human hematopoietic cells between
humans and mice. The reconstitution of the human hematopoietic
system in NOG mice is achieved with the dominant engraftment
of B-cells, in comparison to the myeloid lineage cells [10]. This
technical feature may affect the engraftment of each of the
transplanted cellular subsets in our study. The slow progressive
myeloid tumor cells, such as those involved in myelodysplastic
syndromes and chronic myeloid leukemia in the chronic phase,
were shown to be difficult to engraft in NOD/SCID-b2-
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43] and our unpublished data), suggesting that the engraftment
failure did not always indicate a lack of leukemogenecity of the
transplanted cells. Therefore, our study confirmed the leukemo-
genic activity of the CD34
2 induced APL fraction, although it was
not strong. These results are consistent with the previous in vivo
reports which described the some primary CD34
+/CD38
+ and
CD34
2 AML cells could function as LIC in vivo [44,45].
In conclusion, we demonstrated that the induction of PML-
RARA targeted human CD34
+ cells, including CMP, and led to
their ability to cause APL, and that CD34
2 APL cells have the
capability of maintaining the disease. These findings suggest that it
is not necessary that LIC are always consistent with a cellular
fraction where leukemia-inducing events occur. Tumor-specific
oncogenes, such as PML-RARA, effectively function to form
tumors with specific characteristics in specific hierarchal stages of
myelopoiesis. This model differs from the conventional hierarchal
system of AML, in which LIC possess an immature phenotype as
seen in hematopoietic stem cells. Since AML is a group of
heterogeneous diseases with various causal genetic abnormalities,
Figure 6. PML-RARA targeted human common myeloid progenitors for APL leukemogenesis. (A) The sorting strategy for CD34
+/CD38
2,
CD34
+/CD38
+ and CD34
2/CD33
+ cells. Human cord blood was first separated into CD34
+ and CD34
2 cells by magnetic beads, and then sorted into
three fractions by a FACS vantage instrument. (B) The expression of PML-RARA mRNA in each of the fractions after retroviral transfection. B2M, beta 2
microglobulin. The PML-RARA expression vector was used as a positive control for the PML-RARA analysis. (C) A colony-forming assay using PML-RARA-
transduced CD34
+/CD38
+ and CD34
+/CD38
2 cells. The average of three independent experiments is shown. The data represent the means 6 SD. (D)
The total numbers of colonies of PML-RARA-transduced CD34
+/CD38
+ and CD34
+/CD38
2 cells shown in (C) are highlighted. The data represent the
means 6 SD (n=3). (E) The development of the induced APL from CD34
+/CD38
+ cells in NOG mice. Each sorted fraction from human cord blood, as
seen in (A), was retrovirally transduced with PML-RARA and transplanted into irradiated NOG mice. The percentages were determined by the
frequency of EGFP
+/CD45
+/CD33
+ cells at 16 to 20 weeks after transplantation. Each dot represents a single mouse. The horizontal line represents the
median value. (F) The sorting strategy for common myeloid progenitors (CMP), granulocyte-monocytic progenitors (GMP), and megakaryocyte-
erythrocyte progenitors (MEP). Human cord blood was separated into CD34
+ cells by magnetic beads, CD34
+/CD38
+ cells were sorted out, and were
finally divided into CMP, GMP and MEP by the FACS vantage instrument. (G) The transduction efficiency of PML-RARA in CMP, GMP and MEP.
Representative data are shown. (H) The development of the induced APL from the human hematopoietic progenitors in NOG mice. Each sorted
progenitor fraction from human cord blood, as seen in (F), was retrovirally transduced with PML-RARA and transplanted into irradiated NOG mice. The
percentages were determined by the frequency of EGFP
+/CD45
+/CD33
+ cells at 16 to 20 weeks after transplantation. Each dot represents a single
mouse. The horizontal line represents the median value.
doi:10.1371/journal.pone.0111082.g006
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genesis in other types of AML which display differentiated
leukemic blasts.
Supporting Information
Figure S1 The detection of PML-RARA expression in CD34
+
cells transduced with PML-RARA and their descendent colonies
by qualitative RT-PCR. RT, reverse transcription.
(TIF)
Figure S2 Fluorescent images of the colonies derived from the
EGFP
+ and EGFP
2 fractions of the CD34
+ cells transduced with
PML-RARA.
(TIF)
Figure S3 The results of a quantitative analysis of the PML-
RARA expression in the CD34
+ cells 48 hours after PML-RARA
transduction, the differentiated cells from the resultant colonies
and the induced APL cells. There were significant differences in
the comparison of the expression level of PML-RARA. * indicates
p values ,0.05.
(TIF)
Figure S4 The heat map of the microarray analysis using the
3,439 probes (3,278 genes) that were differentially expressed in the
induced APL (n=3) and the AML other than APL (n=62). The
gene set separated the induced and human primary APL from the
cases of AML other than APL. Red triangles (n=2 from the total
of 16 APL cases) show the clinical APL samples whose microarray
data were obtained in this study.
(TIF)
Figure S5 The heat map of the microarray analysis performed
using the gene set composed of 573 probes (547 genes), which were
specifically expressed in the induced APL in comparison to cases of
AML other than APL and normal promyelocytes. The gene set
clearly clustered the malignant promyelocytes, such as the induced
and human primary APL, apart from the normal promyelocytes.
Red triangles (n=2 of a total 16 APL cases) show the clinical APL
samples whose microarray data were obtained in this study.
(TIF)
Table S1 The sequences of the PCR primers and probes.
(XLSX)
Table S2 KEGG pathway analysis with the gene sets aberrantly
expressed in the induced APL.
(XLSX)
Table S3 The gene set apllied in Figure S5 (573 probes).
(XLSX)
Table S4 The integration sites of PML-RARA in the induced
APL cells.
(XLSX)
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